TOWA GmbH

The journey of Towa International is a story of strategic global expansion rooted in a long-standing Japanese heritage. The narrative begins with its parent company, Towa Pharmaceutical, which was founded in Osaka, Japan, in 1951. For decades, Towa Pharmaceutical established itself as a leading name in Japan's generic drug market, driven by a commitment to providing high-quality, affordable medicines. A pivotal moment in the company's history arrived in 2020. With a vision to extend its reach and impact to patients worldwide, Towa Pharmaceutical made a significant move by acquiring Pensa Pharma, a well-established pharmaceutical platform with a strong presence in Europe and the United States, complete with its own R&D and manufacturing capabilities. This acquisition was the genesis of Towa International, which was established as the international headquarters and global hub for the parent company's operations outside of Japan.

Headquartered in the vibrant pharmaceutical hub of Barcelona, Spain, Towa International became the vessel for carrying Towa's legacy to the world. From its state-of-the-art facilities in Martorelles (Barcelona), which include a major R&D center and one of Europe's largest manufacturing plants for controlled-release products, the company orchestrates its diverse activities. Towa International is dedicated to the research, development, manufacturing, and marketing of complex generic and value-added medicines. Its mission is not just about producing pharmaceuticals; it's about contributing to the sustainability of healthcare systems and, most importantly, bringing genuine smiles to people's faces by improving their health and quality of life. Operating through distinct business units—Towa US (Breckenridge Pharmaceutical), Towa EU, and Towa 2B for worldwide distribution—the company reaches patients in over 30 countries, embodying its ethos: 'From Towa to the World'.